Company intelligence / Profile preview
Aspen Neuroscience
San Diego, California, United Statesaspenneuroscience.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has completed the first two cohorts in its ASPIRO Phase 1/2a trial of ANPD001 in moderate to severe Parkinson's Disease. The primary endpoint is safety and tolerability; so far, no serious adverse events have been observed and all patients were discharged within protocol timelines. Secondary endpoints include improvements in motor symptoms and quality of life. The program now advances to a new commercial formulation.
- Therapeutic areas
- Neurology
- Modalities
- Autologous induced pluripotent stem cell (iPSC)-derived cell therapiesGene-corrected autologous neuron therapy (in research)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
Cell X Technologies (collaboration and license agreement to automate the iPSC manufacturing process)
Beyond the preview
Go deeper on Aspen Neuroscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aspen Neuroscience.